Qiang Zou

Oct 27, 2024 | mdpi.com | Qiang Zou |Shuli Cheng |Anyu Du |Jiayi Chen

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Jun 15, 2024 | arxiv.org | Qiang Zou

arXiv:2407.03352 (cs) View PDF HTML (experimental) Comments: Subjects: Computational Geometry (cs.CG) ACM classes: I.3.5 Cite as: arXiv:2407.03352 [cs.CG] (or arXiv:2407.03352v1 [cs.CG] for this version) https://doi.org/10.48550/arXiv.2407.03352 Submission history From: Qiang Zou [ view email] [v1] Sat, 15 Jun 2024 03:34:33 UTC (85 KB) Bibliographic Tools Bibliographic Explorer Toggle Bibliographic Explorer () Litmaps Toggle Litmaps (What is Litmaps?) scite.ai Toggle scite Smart Citations...

Mar 21, 2024 | sciencedirect.com | Rui Ding |Qiang Zou

Introduction The U.S. Food and Drug Administration (FDA) has approved the combination of nivolumab (Nivo, anti-programmed cell death protein 1 [anti-PD-1]) plus ipilimumab (Ipi, anti-cytotoxic T lymphocyte-associated protein 4 [anti-CTLA-4]) for the treatment of patients with melanoma, colorectal cancer, non-small cell lung cancer, hepatocellular carcinoma, and other cancers.1,2,3,4,5 Although recognized as the most potent and successful immune checkpoint blockade (ICB) combination, serious...